ArticleScientific reports2026
Spatio-temporal clustering characteristics of hepatitis B in China: an 18-year study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To describe the spatiotemporal characteristics of hepatitis B in China and to identify its possible hotspots and potential high-risk areas. A retrospective, province-level ecological analysis of hepatitis B surveillance data. Global Moran's I and local Moran's I were calculated using GeoDa 1.16 to explore the spatial clustering characteristics from 2004 to 2021, and the results of the spatiotemporal scan analysis were obtained using SaTScan 10.1 to identify cluster areas from 2004 to 2018. From 2004 to 2021, the number of hepatitis B incident cases in China increased from 916,426 in 2004 to 976,233 in 2021 (AAPC = 0.38%, P = 0.613), which is not statistically significant. From 2018 to 2021, High-High cluster areas of hepatitis B incidence rates in China were concentrated in the southeast; from 2004 to 2019, High-Low cluster areas of hepatitis B mortality rates were concentrated in Beijing and Shanghai. During the 18-year study period, the crude mortality rate showed a statistically significant decline with an average annual decline of 4.03%. Hepatitis B high-risk areas were concentrated in northwestern and southeastern coastal regions of China, while death counts were clustered in the northwestern and eastern regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.